Corporate Presentation

Corporate presentation

As of September 30, 2021

nasdaq: axgn

Safe harbor statement

This presentation contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events, or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," "goals," and variations of such words and similar expressions are intended to identify such forward- looking statements. The forward-looking statements may include, without limitation, statements regarding our assessment of our internal controls over financial reporting, our growth, the impact of COVID-19, product development, product potential, regulatory process and approvals, APC renovation timing and expense, financial performance, sales growth, product adoption, market awareness of our products, data validation, and our visibility at and sponsorship of, conferences and educational events.

The forward-looking statements are and will be subject to risks and uncertainties, which may cause actual results to differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements contained in this presentation should be evaluated together with the many uncertainties that affect our business and our market, particularly those discussed under Part I, Item 1A., "Risk Factors," of our Annual Report on Form 10-K, for the fiscal year ended December 31, 2020, as well as other risks and cautionary statements set forth in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances, or otherwise.

revolutionizing the science of nerve repair™	2

The Axogen platform for nerve repair

revolutionizing the science of nerve repair™	3

The function of nerves

Nerves are like wires

• Transfer signals across a network
• If cut, data cannot be transferred
• If crushed, short circuits and data corruption may occur

The peripheral nervous system is a vast network from every organ to and from the brain

• Sensory
• Motor
• Autonomic

revolutionizing the science of nerve repair™	4

Axogen is the preeminent nerve repair company with a foundation for long-term sustainable growth

• Exclusively focused on peripheral nerve repair across an expanding set of applications addressing a large market opportunity
• Differentiated platform for nerve repair, anchored by Avance® Nerve Graft
• 10+ years of demonstrated clinical consistency and meaningful recovery outcomes
• 169 peer-reviewed clinical publications

featuring the Axogen product portfolio

(as of September 30, 2021)

• More than 50,000 Avance Nerve Grafts have been implanted since launch

• Avance RMAT designation highlights clinical evidence strength and unmet medical need for improved nerve injury treatments
• Commercial and Professional Education capability to convert experienced surgeons while training the next generation
• Significant barriers to competitive entry
• Solid balance sheet provides resources to execute business plan
• Experienced management team with strong track record of success

revolutionizing the science of nerve repair™	5